Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018

Hucke, Florian; Pinter, Matthias; Hucke, Miriam; Bota, Simona; Bolf, Dajana; Hackl, Monika; Peck‐Radosavljevic, Markus

doi:10.3390/cancers14133093

Cited by 6 publications

(7 citation statements)

References 50 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the group of patients that were diagnosed with HCC between 2010-2018, the overall survival improved significantly to 9.3 months (p < 0.001). [6] We took a closer look at the survival of patients without liver cirrhosis compared to those with cirrhosis. Even though not proven to be statistically significant, the median survival time of patients without cirrhosis was on average longer than those with cirrhosis.…”

Section: Survival Analysis Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in the Epidemiology of Hepatocellular Carcinoma in Carinthia, Austria, 2012–2023

Hucke,

Emmer,

Emmer

et al. 2023

Preprint

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths and remains a major burden on health-care systems worldwide. The incidence of HCC continues to rise globally, despite preventative efforts being made. Aims: This study aimed to investigate epidemiological changes observed in the aetiology and survival outcomes of HCC patients at Klinikum Klagenfurt am Wörthersee between 2012 and 2023. Methods: This was a retrospective, single-centre cohort observational study. Two time-periods (2012-2017 and 2018-2023) were created to enable comparison between the respective intervals. Results: More patients were diagnosed with HCC during the second time-period, proving that the incidence of HCC is rising or the referral patterns changing. The median age of diagnosis was 72.5 years (SD 8.6). Patients were on average 2 years younger in the second time-period compared to the first (p = 0.042). Alcohol remained the leading underlying aetiology of HCC and no statistically significant change was seen over time (p = 0.353). Nevertheless, a clear upward trend in the number of NASH cases was evident over time (n = 15, n = 28 respectively). Nearly half of the patient population did not have a raised AFP at the time of diagnosis. The survival time for HCC patients remained similar between time-periods, with a median overall survival time of 20.5 months (95% CI 16.8-24.2, p = 0.841), despite improvements in management strategies and the availability of new systemic treatments but more advanced stage HCC was documented in the second period. An increasing number of HCC patients without liver cirrhosis were identified during the second time-period (n = 22, n= 47 respectively, p = 0.005). NASH was the most common underlying aetiology in patients without liver cirrhosis (50%), compared to alcohol use in being the primary cause in cirrhotic patients (p < 0.001). Conclusion: HCC continues to be an important health concern in our society. The number of HCC patients without liver cirrhosis is steadily increasing, with NAFLD/ NASH, due to underlying life-style diseases playing an important aetiological role. Continued efforts should be made to prevent HCC and to screen at-risk population groups. Preventative strategies and screening techniques should be adjusted in light of the changing epidemiological landscape of HCC.

show abstract

Section: Survival Analysis Discussionmentioning

confidence: 99%

“…[5] Between 2010 and 2018 a total of 7,146 individuals were diagnosed with HCC in Austria, of which 75% were male and 25% were female. [6] HCC mainly develops in the setting of underlying liver cirrhosis. [1] Hepatitis B Virus (HBV) is still the leading underlying cause of HCC globally, due to its high prevalence in Asia and Africa.…”

Section: Introductionmentioning

confidence: 99%

Changes in the Epidemiology of Hepatocellular Carcinoma in Carinthia, Austria, 2012–2023

Hucke,

Emmer,

Emmer

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Among women, there were comparable changes but at a higher level of significance. Studies from other countries have reported improvements in survival from ICC varying from moderate [ 24 , 25 ] to non-significant [ 19 ]. Substantial improvements have been obtained only among patients undergoing surgical treatment [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…In the United States, a study based on data from the Surveillance, Epidemiology, and End Results database found no significant change in survival from ICC between 1975 and 2016 [ 19 ], with a substantial improvement being reported only in patients undergoing surgical treatment [ 23 ]. A moderately favourable trend has been observed in some European countries during the past two decades [ 5 , 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Trends in Liver Cancer Incidence and Survival in Italy by Histologic Type, 2003–2017

Mancini

Bucchi

Zamagni

et al. 2022

Cancers

View full text Add to dashboard Cite

(1) Background: Liver cancer in Italy is characterised by one of the highest incidence rates worldwide outside of Asia coupled with comparatively favourable survival figures. The objective of this study was to evaluate the most recent epidemiologic trends of the disease. (2) Methods: Thirteen cancer registries covering a population of about 12,740,000 (21% of the national population) made available the records of 35,574 cases registered between 2003 and 2017. Trends in age-standardised (Europe 2013) incidence rates were analysed using the results of age–drift models. Trends in survival were analysed using 1-year, 2-year, 5-year and 10-year net survival (NS) and 5|1-year and 5|2-year conditional NS. (3) Results: Over the study period, the average annual incidence rates per 100,000 persons were 29.4 (men) and 9.4 (women) for total liver cancer; 14.6 and 3.5 for hepatocellular carcinoma (HCC); 1.8 and 1.1 for intrahepatic cholangiocarcinoma (ICC); and 13.0 and 4.8 for the ‘other liver cancer types’ group. The incidence of total liver cancer and HCC decreased significantly for both sexes. For total liver cancer, the estimated average annual percent change was −1.6% among men and −2.1% among women. For HCC, the change was −1.3% among men and −2.7% among women. ICC followed an opposite trend. For men, the risk of HCC had two peaks, one in the birth cohorts of 1928 and 1933 and another, more moderate peak in the cohort of 1958. Men and women exhibited comparable improvements in both early and mid-term conditional NS from HCC. In 2013–2017, 5-year NS was 28.9% (95% CI: 27.3%; 30.6%) for men and 30.1% (95% CI: 26.9%; 33.5%) for women. The uptrend in survival from ICC was less pronounced and was weakly significant, with a 5-year NS in 2013-2017 of 13.9% (95% CI: 10.8%; 17.3%) for men and 17.4% (95% CI: 13.5%; 21.7%) for women. (4) Conclusions: The opposite incidence trends of HCC and ICC confirm a pattern observed in other populations. The generalised, albeit slow, improvement in survival from HCC indicates a trend towards earlier detection coupled with improvements in treatments.

show abstract

“…Hepatocellular carcinoma (HCC) is a highly prevalent malignant disease with high mortality rate, and is currently one of the top three cancers in the world in terms of mortality (Hucke et al., 2022 ). When diagnosed, only a small percentage of patients can be treated by surgical resection or liver transplantation to obtain a relatively ideal therapeutic effect (Tsai et al., 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Impact of particle size of multivesicular liposomes on the embolic and therapeutic effects in rabbit VX2 liver tumor

et al. 2023

View full text Add to dashboard Cite

Transcatheter arterial chemoembolization (TACE) is usually considered more efficacious in the local treatment of parenchyma-sparing hepatocellular carcinoma (HCC). At present, embolic agents commonly used in TACE, include DC pellets, Hepasphere, Lipiodol, etc. Except that iodine oil is a viscous fluid embolic agent, other solid microsphere particles used clinically range from 70 to 700 µm, among which 100 to 300 µm is the most commonly used. With the technology development of micro-invasive interventional therapy, the specific distal embolization through TACE to occlude tumor arterial blood supply in patients with HCC is also required more accurately. Effective terminal embolization is considered to be a preferred option for TACE therapy due to significantly improving the survival rate of patients and preserving liver function. In this article, we prepared the multifunctional multivesicular liposomes (IVO-DOX-MVLs) (<100 µm) that can simultaneously encapsulate ioversol and doxorubicin based on the high-phase transition temperature ( T m ) lipid ingredients, and evaluated its local artery embolization and therapeutic effect in rabbit VX-2 tumor model. The influence of particle size on occlusion and therapeutic effect of MVLs on rabbit VX-2 liver tumor models were well evaluated, including the tumor volume change, tumor growth rate, and necrosis rate, which were evaluated by magnetic resonance (MR). MVL samples with average particle size distribution of 50–60 µm exhibited fewer off-target embolization. Through TACE, IVO-DOX-MVLs were directly transported to the tumor tissues, playing roles of embolization performance, CT imaging effect, and local tumor killing effect. The feasibility of MVLs as a multifunctional embolic agent in its clinical application can be further improved by optimization of lipid composition and preparation process.

show abstract

Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018

Cited by 6 publications

References 50 publications

Changes in the Epidemiology of Hepatocellular Carcinoma in Carinthia, Austria, 2012–2023

Changes in the Epidemiology of Hepatocellular Carcinoma in Carinthia, Austria, 2012–2023

Trends in Liver Cancer Incidence and Survival in Italy by Histologic Type, 2003–2017

Impact of particle size of multivesicular liposomes on the embolic and therapeutic effects in rabbit VX2 liver tumor

Contact Info

Product

Resources

About